The uterine volume is dramatically decreased after hematopoietic stem cell transplantation during childhood regardless of the conditioning regimen.


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
04 2023
Historique:
received: 23 07 2022
revised: 22 12 2022
accepted: 28 12 2022
medline: 10 4 2023
pubmed: 11 1 2023
entrez: 10 1 2023
Statut: ppublish

Résumé

To study the impact of hematopoietic stem cell transplantation (HSCT) on the uterine volume of childhood acute leukemia (AL) survivor depending on age at HSCT and the type of myeloablative conditioning regimen. Thirteen French University Teaching Hospitals. Prospective cohort study. Eighty-eight women who underwent HSCT during childhood or adolescence for AL compared to a control group. A multicentric prospective national study compared the uterine volume in a cohort of childhood AL survivor adult women treated with HSCT, matched 1:1 to control women. Pelvic magnetic resonance imaging scans included diffusion-weighted imaging sequences. Scans were centralized for a double-blinded reading by 2 radiologists. Uterine volume, uterine body-to-cervix ratio, and apparent diffusion coefficient. The mean age at HSCT was 9.1 ± 0.3 years with a mean follow-up duration of 16.4 ± 0.5 years. The cohort of 88 HSCT survivor women was composed of 2 subgroups depending on the myeloablative conditioning regimen received: an alkylating agent-based regimen group (n = 34) and a total body irradiation (TBI)-based regimen group (n = 54). Among the 88 women, 77 were considered as having a "correct hormonal balance" with estrogens supplied by hormone replacement therapy (HRT) for premature ovarian insufficiency (POI) or because of a residual ovarian function. In the control group (n = 88), the mean uterine volume was 79.7 ± 3.3 mL. The uterine volume significantly decreased in all HSCT survivor women. After the alkylating agent-based regimen, the uterine volume was 45.3 ± 5.6 mL, corresponding to a significant volume reduction of 43.1% (28.8-57.4%) compared with that of the control group. After TBI, the uterine volume was 19.6 ± 1.9 mL, corresponding to a significant volume reduction of 75.3% (70.5%-80.2%) compared with that of the control group. After the alkylating agent-based regimen, the uterine volume dramatically decreased in women with POI without HRT compared with that in those with a correct hormonal balance (15.2 ± 2.6 vs. 49.3 ± 6 mL). In contrast, after TBI, the uterine volume was similar in all women, with no positive effect of hormonal impregnation on the uterine volume (16.3 ± 2.6 vs. 20.1 ± 2.2 mL, respectively). The uterine volume was diminished after HSCT, regardless of the conditioning regimen. The physiopathology needs to be further investigated: specific impact of a high dose of an alkylating agent; impact of hormone deprivation around puberty; poor compliance to HRT; or different myometrial impact of HRT compared with endogenous ovarian estrogens? ClinicalTrials.gov/NCT03583294 (enrollment of the first subject, November 11, 2017; enrollment of the last subject, June 25, 2021).

Identifiants

pubmed: 36627013
pii: S0015-0282(22)02132-X
doi: 10.1016/j.fertnstert.2022.12.040
pii:
doi:

Substances chimiques

Alkylating Agents 0
Estrogens 0

Banques de données

ClinicalTrials.gov
['NCT03583294']

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

663-672

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Blandine Courbiere (B)

Department of Gynecology-Obstetric and Reproductive Medicine, AP-HM, Hôpital La Conception/Aix-Marseille Université, IMBE, CNRS, IRD, Avignon Université, Marseille, France. Electronic address: blandine.courbiere@univ-amu.fr.

Benjamin Drikes (B)

Department of Radiology, University Teaching Hospital Timone, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.

Anaïs Grob (A)

Department of Radiology, University Teaching Hospital Timone, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.

Zeinab Hamidou (Z)

CEReS Research Unit EA 3279 and Department of Public Health, Hôpital de la Timone, Marseille, France.

Paul Saultier (P)

Department of Pediatric Hematology, Immunology and Oncology, AP-HM, La Timone Children's Hospital, Marseille, France; Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France.

Yves Bertrand (Y)

Department of Pediatric Hematology and Oncology, University Hospital of Lyon, Lyon, France.

Virginie Gandemer (V)

Department of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France.

Dominique Plantaz (D)

Department of Pediatric Hematology-Oncology, University Hospital of Grenoble, Grenoble, France.

Geneviève Plat (G)

Department of Pediatric Hematology and Oncology, University Hospital of Toulouse, Toulouse, France.

Maryline Poirée (M)

Department of Pediatric Hematology and Oncology, University Hospital L'Archet, Nice, France.

Stéphane Ducassou (S)

Department of Pediatric Hematology and Oncology, University Hospital of Bordeaux, Bordeaux, France.

Cécile Pochon (C)

Department of Pediatric Hematology and Oncology, Children's Hospital of Brabois, Vandoeuvre-Les-Nancy, France.

Jean-Hugues Dalle (JH)

Department of Hematology and immunology, Hôpital Robert-Debré, GHU APHP-Nord Université de Paris-Cité, Paris, France.

Sandrine Thouvenin (S)

Department of Pediatric Onco-hematology, CHU de Saint-Etienne, Saint-Etienne, France.

Catherine Paillard (C)

Department of Pediatric Hematology-Oncology, University Hospital, Strasbourg, France.

Justyna Kanold (J)

Department of Pediatric Hematology and Oncology, CIC Inserm 501, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.

Anne Sirvent (A)

Department of Pediatric Onco-Hematology, University Hospital of Montpellier, Montpellier, France.

Christine Rousset-Jablonski (C)

Département de Chirurgie Oncologique, Centre Léon Bérard, Lyon, France, and Hospices Civils de Lyon, Département de Gynécologie-Obstétrique, Groupe Hospitalier Sud, Pierre Benite Cedex, France; INSERM U1290 RESHAPE RESearch in HealthcAre PErformance, Université Lyon 1, Lyon, France.

Solène Duros (S)

Département de Gynécologie-Obstétrique et Reproduction Humaine, CHU Rennes, Rennes, France.

Aurore Gueniffey (A)

Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), La Tronche, France.

Clementine Cohade (C)

Department of Reproductive Medicine, Toulouse University Hospital, Toulouse, France.

Samir Boukaidi (S)

Department of Obstetrics and Gynecology and Reproductive Medicine, CHU de Nice, Archet 2 Hospital, Nice, France.

Sandrine Frantz (S)

Service de Chirurgie Gynécologique et Médecine de la reproduction, Centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie-Raba-Léon, Bordeaux cedex, France.

Mikael Agopiantz (M)

Department of Reproductive Medicine, CHRU de Nancy, Université de Lorraine, Nancy, France INSERM U1256, Université de Lorraine, Vandœuvre-lès-Nancy, France.

Catherine Poirot (C)

Department of Hematology, AYA Unit, Saint Louis Hospital, Paris, France, Médecine Sorbonne Université, Site Pitié Salpêtrière, Paris, France, and Department of Reproductive Biology, Cochin Hospital AP-HP, Paris, France.

Anne Genod (A)

Service de Gynécologie-Obstétrique, Université Jean-Monnet, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France.

Olivier Pirrello (O)

Assisted Reproductive Technique Unit, CMCO, University Hospital of Strasbourg, Schiltigheim, France.

Anne-Sophie Gremeau (AS)

Department of Gynecologic Surgery and IVF, Clermont-Ferrand, University Hospital Clermont-Ferrand, Clermont-Ferrand, France.

Sophie Bringer-Deutsch (S)

Service de Gynécologie-Obstétrique et Médecine de la reproduction, CHU Arnaud-de-Villeneuve, Montpellier, France.

Pascal Auquier (P)

CEReS Research Unit EA 3279 and Department of Public Health, Hôpital de la Timone, Marseille, France.

Gérard Michel (G)

CEReS Research Unit EA 3279 and Department of Public Health, Hôpital de la Timone, Marseille, France; Department of Pediatric Hematology, Immunology and Oncology, AP-HM, La Timone Children's Hospital, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH